Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's ...

GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, Germany/BOSTON, USA – September 12, 2024 – CureVac N.V ...

Before the recalls, Zantac was sold by GSK, US pharma giant Pfizer, French drug company Sanofi and Boehringer Ingelheim, based in Germany. GSK said in a press release on Tuesday: "GSK welcomes ...

TÜBINGEN, GERMANY and BOSTON, MA - GlaxoSmithKline (NYSE:GSK) has reported encouraging Phase 2 results for its mRNA-based seasonal influenza vaccine, which utilizes technology from ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September ...

GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...

GSK has upgraded its longstanding alliance with ... Merck eyes deal with Afrigen Biologics In other mRNA vaccine news today, Germany’s Merck KGaA revealed that it has signed a non-binding ...

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

Patients with advanced SSC of the anal canal have a marked survival benefit when immunotherapy is added to standard-of-care ...

inventory building in the US and strong demand in Germany. GSK's HIV business, run through joint venture company ViiV Healthcare, also had a good quarter with sales up 14% to £1.4 billion ...